行情

SUPN

SUPN

Supernus Pharma
NASDAQ

实时行情|Nasdaq Last Sale

17.09
-0.20
-1.16%
已收盘, 16:00 04/02 EDT
开盘
17.10
昨收
17.29
最高
17.58
最低
16.55
成交量
53.70万
成交额
--
52周最高
39.15
52周最低
13.12
市值
8.98亿
市盈率(TTM)
8.12
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测SUPN价格均价为25.67,最高价位32.00,最低价为20.00。

EPS

SUPN 新闻

更多
  • Supernus Provides Business Update
  • GlobeNewswire · 3天前
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • Need To Know: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Insiders Have Been Buying Shares
  • Simply Wall St. · 03/16 15:34
  • The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
  • Benzinga · 03/13 11:52

所属板块

制药
+2.64%
制药与医学研究
+2.80%

热门股票

代码
价格
涨跌幅

SUPN 简况

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.
展开

微牛提供Supernus Pharmaceuticals Inc(NASDAQ-SUPN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的SUPN股票新闻,以帮助您做出投资决策。